Bella Biologics, Inc.
Developer of an in vivo gene‑editing approach that targets precursor immune cells to reprogram B‑cells and T‑cells to produce therapeutic antibodies. Offers custom antibody design, high‑throughput screening, and human B‑cell–derived production workflows for research and development applications. Describes a modular platform intended for scalable, low‑cost manufacturing and long‑term stability.
Industries
N/A
Products
In vivo immune‑cell gene‑editing platform
A platform for in vivo editing of precursor immune cells using plasmid delivery with engineered recombination signals and RAG‑mediated inserts to reprogram B‑cells or T‑cells to produce therapeutic antibodies.
In vivo immune‑cell gene‑editing platform
A platform for in vivo editing of precursor immune cells using plasmid delivery with engineered recombination signals and RAG‑mediated inserts to reprogram B‑cells or T‑cells to produce therapeutic antibodies.
Services
Custom Antibody Design & Screening
Quote‑based service for custom antibody engineering, discovery, screening and validation for research use. Supports multiple antibody formats and human B‑cell–derived production workflows.
Custom Antibody Design & Screening
Quote‑based service for custom antibody engineering, discovery, screening and validation for research use. Supports multiple antibody formats and human B‑cell–derived production workflows.
Expertise Areas
- In vivo gene editing of immune cells
- Lymphocyte (B‑cell and T‑cell) reprogramming
- Antibody engineering and format design
- High‑throughput antibody discovery and screening
Key Technologies
- Plasmid‑based gene delivery
- Engineered recombination signal sequences (eRSS)
- RAG‑mediated genomic insertion
- In vivo lymphocyte targeting